Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical, Inc. (LFCR) reports developments as a fully integrated injectables CDMO focused on sterile pharmaceutical products. The company provides development, fill and finish services for syringes, vials and cartridges, including complex formulations, and manufactures injectable-grade hyaluronic acid for biopharmaceutical and biotechnology customers.
Company news commonly covers financial results, revenue and Adjusted EBITDA guidance, commercial site transfer programs, technical transfer and PPQ work, new CDMO manufacturing service agreements, customer program expansions, cost-containment initiatives, biomanufacturing conference participation and Nasdaq inducement equity grants.
Lifecore Biomedical, a fully integrated CDMO, has successfully closed a $24.3 million private placement of common stock. The company issued 5,928,775 shares at $4.10 per share to new and existing investors. Lifecore plans to use the proceeds for working capital, operations, and general corporate purposes.
Paul Josephs, president and CEO of Lifecore, expressed satisfaction with the investors' confidence, viewing it as support for the new management team, value creation plan, and market opportunities. The common stock was issued under an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933 and is not registered for public sale in the United States.
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced that it will release its financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, before the market opens. The company will also host a webcast at 8:30 a.m. Eastern Time on the same day.
During the webcast, Lifecore's senior management team will discuss the quarterly financial results and provide an update on recent corporate developments. Investors and interested parties can access the live webcast or archived version through the Investor Events & Presentations page on Lifecore's website at https://ir.lifecore.com/events-presentations.
Lifecore Biomedical (NASDAQ: LFCR) has been selected by Lindy Biosciences as their preferred CDMO to support process development and commercial scale-up for their innovative microglassification formulation technology. The multi-year agreement could potentially bring in over $5 million in revenue for Lifecore. Lindy's technology aims to transform biologic therapeutics delivery from intravenous to subcutaneous self-administration, enabling higher concentration doses.
Lifecore was chosen after a competitive process due to their expertise in sterile injectable pharmaceuticals and complex formulations. This partnership positions Lifecore as a key player in the manufacture and fill/finish of next-generation biotherapeutic formulations, potentially benefiting patients worldwide.
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated CDMO, has announced its participation in four upcoming industry events. These include:
- The Medical Aesthetic Injectable Summit 2024 in Marbella, Spain (Oct 4-5), where Darren Hieber will join a roundtable on Filler Raw Materials.
- CPHI Worldwide 2024 in Milan, Italy (Oct 8-10).
- The 21st Annual Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference in Phoenix, AZ (Oct 22-23).
- The 14th Annual Partnership Opportunities in Drug Delivery Conference in Boston, MA (Oct 28-29), featuring a presentation by Ryan Swanson on avoiding injectables pitfalls.
At these events, Lifecore will engage in business development activities, host booth meetings, and interact with existing and prospective customers and partners.
Lifecore Biomedical (NASDAQ: LFCR) has announced that its new high-speed, multi-purpose 5-head isolator filler is now GMP-ready and operational. This state-of-the-art technology more than doubles the company's current capacity for fill/finish services of prefilled syringes, vials, and cartridges. The system offers enhanced speed and aseptic isolation required for the latest sterile injectable pharmaceutical and biopharmaceutical products.
The new filler positions Lifecore to meet increased industry controls, such as the EU's Annex 1 requirements, while providing operational efficiencies. It is expected to improve Lifecore's leadership in handling complex formulations and help diversify its customer base by supporting projects for less viscous and less complex protein, peptide, and antibody products.
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the upcoming Craig-Hallum Bioprocessing Conference on September 19, 2024. The event will be held virtually, featuring a fireside chat with Lifecore's leadership:
- Paul Josephs, President and CEO
- Ryan Lake, CFO
The fireside chat is scheduled for 3:30 p.m. Eastern on September 19. In addition to the chat, the executives will participate in one-on-one meetings during the conference. A webcast replay of the fireside chat will be made available on Lifecore's investor website following the event.
Lifecore Biomedical (NASDAQ: LFCR) has announced that it has regained compliance with Nasdaq listing requirements. The company received written notice from the Nasdaq Listing Qualifications Department confirming its compliance with Rule 5250(c), which requires timely filing of periodic financial reports, and Rule 5620(a), which mandates annual stockholder meetings. As a result, Nasdaq has ceased any delisting actions against Lifecore's common stock.
However, Lifecore will be subject to a Mandatory Panel Monitor until September 4, 2025. During this period, if the company fails to comply with Rule 5250(c) again, it will not be allowed to provide a compliance plan or receive a cure period. Instead, Nasdaq would issue a delisting determination letter, after which Lifecore could request a new hearing with a Hearing Panel.
Lifecore Biomedical (NASDAQ: LFCR) has appointed Brikkelle Thompson as Senior Vice President of Human Resources. With nearly 25 years of HR leadership experience, including 14 years in medical technology and healthcare industries, Thompson will focus on enhancing the company's performance-driven culture and strengthening the team. Her background includes roles at Teleflex, Nonin Medical, and Medtronic, where she demonstrated expertise in building top-performing teams and implementing strategic HR initiatives.
CEO Paul Josephs emphasized the importance of corporate culture and talent in executing Lifecore's growth strategy. Thompson's appointment is seen as a strategic move to align the company's mission, values, and team towards consistent and meaningful growth. Her experience spans from small organizations to Fortune 100 companies in both public and private sectors.
Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has granted equity awards to its newly hired CFO, Ryan D. Lake. The awards, approved on September 3, 2024, include:
1. A Restricted Stock Unit (RSU) award for 262,500 shares, vesting over five years.
2. A Performance Stock Unit (PSU) award for up to 750,000 shares, vesting based on stock price performance over five years.
These awards were granted as inducement equity under Nasdaq Listing Rule 5635(c)(4) and Lifecore's Equity Inducement Plan. The PSU award is tied to stock price targets ranging from $5.00 to $30.00 per share.
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the 17th Annual Barrington Research Virtual Fall Investment Conference. The event is scheduled for Thursday, September 12, 2024, and will be held virtually.
During the conference, Lifecore's management team will engage in one-on-one meetings with investors. This participation provides an opportunity for the company to connect with potential investors and discuss its operations, strategies, and future prospects in the CDMO industry.
The announcement highlights Lifecore's commitment to investor relations and its efforts to maintain open communication with the financial community. By participating in such events, the company aims to increase its visibility among investors and provide insights into its business model and growth potential.